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African trypanosomosis (AT) is a chronically debilitating parasitic disease of medical and 
economic importance for the development of sub-Saharan Africa. The trypanosomes 
that cause this disease are extracellular protozoan parasites that have developed effi-
cient immune escape mechanisms to manipulate the entire host immune response to 
allow parasite survival and transmission. During the early stage of infection, a profound 
pro-inflammatory type 1 activation of the mononuclear phagocyte system (MPS), involv-
ing classically activated macrophages (i.e., M1), is required for initial parasite control. Yet, 
the persistence of this M1-type MPS activation in trypanosusceptible animals causes 
immunopathology with anemia as the most prominent pathological feature. By contrast, 
in trypanotolerant animals, there is an induction of IL-10 that promotes the induction 
of alternatively activated macrophages (M2) and collectively dampens tissue damage. 
A comparative gene expression analysis between M1 and M2 cells identified galectin-3 
(Gal-3) and macrophage migration inhibitory factor (MIF) as novel M1-promoting factors, 
possibly acting synergistically and in concert with TNF-α during anemia development. 
While Gal-3 enhances erythrophagocytosis, MIF promotes both myeloid cell recruitment 
and iron retention within the MPS, thereby depriving iron for erythropoiesis. Hence, the 
enhanced erythrophagocytosis and suppressed erythropoiesis lead to anemia. Moreover, a 
thorough investigation using MIF-deficient mice revealed that the underlying mechanisms 
in AT-associated anemia development in trypanosusceptible and tolerant animals are 
quite distinct. In trypanosusceptible animals, anemia resembles anemia of inflammation, 
while in trypanotolerant animals’ hemodilution, mainly caused by hepatosplenomegaly, 
is an additional factor contributing to anemia. In this review, we give an overview of 
how trypanosome- and host-derived factors can contribute to trypanosomosis- 
associated anemia development with a focus on the MPS system. Finally, we will discuss 
potential intervention strategies to alleviate AT-associated anemia that might also have 
therapeutic potential.
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iNTRODUCTiON
African trypanosomes are extracellular protozoan parasites 
causing debilitating diseases of medical, veterinary, and socio­
e conomical importance that adversely affect the economic develop­
ment of sub­Saharan Africa (1–3). The distribution of the disease 
coincides with the habitat of the tsetse fly vector (Glossina spp.), 
and is called the tsetse fly “belt” or is sometimes referred to as 
“green desert” due to the fact that ~10 million km2 of potential 
fertile land is rendered unsuitable for cultivation (3). Within 
this area, the majority of the 39 tsetse­infested countries are 
underdeveloped, poor, heavily indebted, food­deficit countries 
due to the lack of productive animals as far as meat/milk pro­
duction and draft power are concerned, resulting in an annual 
economic loss of about 5 billion US$ (4, 5). In addition, about 
60 million people living in this belt are at potential risk of infec­
tion with an estimated mortality rate of about 10,000 per year 
(6). Due to the low incidence of African trypanosomiasis, it is 
also considered a neglected disease. The disease caused by these 
extracellular hemoflagellates in humans is known as “sleeping 
sickness” or human African trypanosomiasis (HAT), while 
in domestic animals it is called “nagana” or animal African 
trypanosomiasis (AAT) (7). As far as HAT is concerned, two 
distinct subspecies of Trypanosoma brucei are responsible for 
the disease: (i) Trypanosoma brucei gambiense, typically found 
in western and central Africa (representing 98% of all cases, 
with humans as main reservoir), causes a chronic form of HAT 
(a few months to over several years) and (ii) Trypanosoma brucei 
rhodesiense, found in eastern and southern Africa [representing 
about 2% of all HAT cases due to the fact it is a zoonosis form 
with animals as main reservoir and humans being occasionally 
infected (8, 9)], generally causes an acute form of HAT leading 
to death within a few months if left untreated (6, 10, 11). HAT is 
characterized by two successive stages: an early hemolymphatic 
stage, whereby the parasites are observed in the peripheral blood 
and the lymphatic system, and a later meningoencephalitic stage, 
where parasites cross the blood–brain barrier and proliferate 
in the cerebral spinal fluid resulting in neurological complica­
tions/cerebral pathology and death if left untreated (12, 13). 
As far as AAT is concerned, the strictly intravascular parasites 
Trypanosoma congolense, as well as Trypanosoma vivax, can be 
considered the most important causative agents (14). Yet, also 
Trypanosoma brucei brucei and Trypanosoma evansi, residing 
both in intravascular as well as extravascular spaces within their 
host, have been documented to contribute to livestock infections 
(14–16). In contrast to game animals, where these parasites cause 
only mild infections, the disease in domestic animals is severe 
and often fatal (5, 17, 18).
Various methods have been implemented to control African 
trypanosomiasis (19); including (i) vector control (20), (ii) reduc­
ing the proximity of livestock to reservoir hosts, (iii) development 
op trypanotolerant livestock (disease­resistant breeds) (5, 21), 
and (iv) using trypanocidal drugs (22). Yet, their success is lim­
ited due to the fact that these techniques are often used locally and 
not necessarily in a coordinated fashion (23), game animals func­
tion as parasite reservoir without exhibiting pathological signs 
(24), and the rapid emergence of drug­resistant trypanosomes, 
thereby undermining their efficacy and leading to the widespread 
outbreaks of trypanosomiasis (19, 25, 26).
The main factor hampering control over African trypanoso­
miasis is the fact that these parasites have evolved very efficient 
immune escape mechanisms and are able to manipulate the 
entire host immune response to avoid elimination [reviewed 
in Ref. (27)]. Accordingly, an alternative approach to tackle 
African trypanosomiasis is targeting the infection­associated 
immunopathology. For example, in HAT patients neurological 
complications are the major pathological feature, yet, an addi­
tional complication observed during the hemolymphatic stage 
is anemia (28, 29). In AAT, anemia is considered the most 
prominent immunopathological disease­related feature and the 
major cause of death due to Nagana (30). Importantly, in cattle, 
trypanotolerance has been referred to as the capacity of an animal 
to control severe anemia development which is assumed to be 
independent of parasitemia levels (21, 30). Moreover, Naessens 
et al. (31) showed using chimeric studies between trypanotolerant 
N’Dama (i.e., ancient cattle breeds/West African longhorn, Bos 
taurus) and trypanosusceptible Boran (more recently introduced 
cattle breeds, Bos indicus) that trypanotolerance is composed of 
two traits, (i) a better capacity to control parasitemia which is 
independent of the genetic origin of the hematopoietic tissue 
and (ii) a better ability to control anemia which is dependent 
on hematopoietic cells and thus a tolerant hematopoietic tissue 
genotype. Moreover, the capacity to control anemia is considered 
as the most important trait of the more resistant/trypanotolerant 
cattle (32). Yet, not only the genetic background (N’Dama versus 
Boran) but also other factors such as the age of the host, type 
of trypanosome spp. infecting, and nutrition can contribute to 
bovine trypanotolerance (33–38).
Tsetse fly mediated (i.e., natural infection mode) and experi­
mental (i.e., using clonal parasites) murine models have been 
developed to allow a more detailed unraveling of the underlying 
mechanisms of trypanosomiasis­associated anemia develop­
ment. Although most trypanosomes cannot be considered 
natural pathogens for rodents, experimental infections in mice 
may offer good models to identify the molecular pathways that 
mediate particular traits or pathological features such as anemia 
(39). Moreover, the genetic background of the mice was also 
found to contribute to susceptibility or tolerance as far as anemia 
is concerned, whereby during T. brucei and T. congolense infec­
tion C57BL/6 mice exhibited severe anemia (yet low parasitemia) 
while BALB/c mice exhibited greatly reduced anemia (yet higher 
parasitemia) (40, 41). However, there are some differences in 
the phenotype. Indeed, even the most tolerant mouse strains 
eventually succumb to the infection, while in the absence of 
other stress factors, tolerant cattle survive such challenge. So far, 
studies in murine models focusing mainly on “clonal or natural 
(tsetse transmitted)” T. congolense and T. brucei parasites have 
shown that similar as in the bovine system, chronic anemia does 
not seem to correlate with parasitemia or survival, but rather is 
a result of infection­elicited host responses, where B­cells do not 
seem to play a major role (40, 42). By contrast, cells of the mono­
nuclear phagocyte system (MPS, i.e., tissue resident myeloid cells 
and inflammation­elicited/inflammatory myeloid cells derived 
from circulating monocytes) have been shown to play a key role 
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in infection­associated pathogenicity/anemia development (43). 
Moreover, due to their sensing ability towards pathogen­ and 
host­derived signals in the environment, their phagocytic capac­
ity and functional plasticity in response to these signals, cells 
of the MPS are considered as a crucial immune population in 
both health and disease. A large number of studies, including our 
work, have begun to establish how the ontogeny/differentiation 
of these cells is tailored during the course of African trypano­
some infections. In this review, we aim at (i) giving an overview 
of how trypanosome­derived and host­derived factors can affect 
the MPS and contribute to trypanosomosis­associated anemia 
development and (ii) discussing on potential intervention strate­
gies to alleviate African trypanosomosis (AT)­associated anemia 
that might also have therapeutic potential.
ANeMiA DeveLOPMeNT DURiNG 
AFRiCAN TRYPANOSOMe iNFeCTiONS
Myeloid Cells As Key Players in the 
Parasite–Host interaction and 
Trypanosomiasis-Associated Acute 
Anemia Development
The interaction between African trypanosomes and their mam­
malian host elicits the sequential activation of innate and adaptive 
immune responses. Being extracellular parasites, they are con­
tinuously confronted with the host’s immune system. However, 
through co­evolution, a well­balanced growth regulation system 
developed that allows sufficiently long parasite survival without 
killing its host to ensure transmission (44). This intricate balance 
consists of (i) a potent type 1 cellular/pro­inflammatory immune 
response and (ii) a strong humoral antiparasite B­cell response 
during the most prominent first peak parasitemia which col­
lectively allows parasite control and temporary host resistance 
(42, 45). However, to avoid complete elimination, these extracellu­
lar parasites have developed various immune evasion mechanisms 
(consisting of antigenic variation, immunosuppression and B­cell 
depletion/loss of B­cell memory) to ensure progression/chronic­
ity and transmission (46–50). Moreover, the early “beneficial” 
pro­inflammatory immune response mediated by the activated 
MPS, can culminate into severe collateral damage to the host if 
persistent. In this context, the level of the inflammatory immune 
response triggered and the capacity of the host to control this 
response determines whether immunopathology (i.e., anemia 
and tissue damage) develops and allows discriminating between 
trypanosusceptible and trypanotolerant animals (see Figure 1).
Experimental murine models, using gene­specific­deficient 
animals, have been very crucial in trying to unravel the mecha­
nisms implicated in trypanosomiasis­associated pathogenicity 
and anemia in particular. In general, anemia occurs during all 
stages of a typical African trypanosome infection and can be 
divided into distinct phases (see Figure  1), (i) an early/acute 
stage whereby following/coinciding peak parasitemia clearance 
there is occurrence of a drastic drop in red blood cells (RBCs) 
numbers (i.e., acute or consumptive anemia) which is followed 
by a recovery phase and (ii) a more late/chronic phase coinciding 
with progressive anemia development. Accumulating evidence 
points to a pivotal role of myeloid cells in anemia development 
(see Figure  1). Hereby, their plasticity toward environmental 
triggers allows discriminating between classically activated 
macrophages (i.e., M1) and alternatively activated macrophages 
(i.e., M2). Moreover, the prevalence of M1 or M2 during the 
course of infection correlates with the severity of anemia (43). 
Consequently, both pro­ and anti­inflammatory cytokines have 
been shown to be implicated in anemia onset and progression 
(51). In this section, different parasite­ and host­derived factors 
contributing to both myeloid cell activation and to acute and 
chronic anemia development will be discussed. To this end, two 
different murine African trypanosome models, i.e., the T. brucei 
and T. congolense infection model, will be compared. It is impor­
tant to mention that within the murine African trypanosomiasis 
model, T. brucei infections are associated with severe anemia 
(i.e., a more susceptible model) and T. congolense infections with 
reduced anemia (i.e., a more tolerant model). Emphasis will be 
put on the more thoroughly investigated murine T. brucei infec­
tion model. However, over the years more and more research has 
been conducted using the murine T. congolense infection model. 
Hence, we will also discuss, if possible, the common or distinct 
features underlying anemia development in both models.
Trypanosome-Derived Factors That Affect Myeloid 
Cell Activation during the Early/Acute Stage of 
Trypanosome Infection
Upon the bite of a trypanosome­infected tsetse fly, metacyclic 
parasites expressing a heterologous variant surface glycoprotein 
(VSG) coat (i.e., metacyclic VSG) that prevents early detection/
elimination (52), are inoculated. Already during the early stage of 
infection, trypanosomes release factors that alone or in concert 
with saliva components can dampen/impair the activation of 
the host’s immune response, to generate a privileged “micro”­ 
environment to allow infection establishment [reviewed in Ref. (27) 
and shown in Figure  2, left panel]. Of note, with respect to 
parasite­released factors that could modulate the host MPS, most 
research so far has been performed using the model parasite 
T. brucei and remain to be determined for the T. congolense 
model. For instance, studies using the T. brucei model parasite 
revealed that they harbor a kinesin heavy chain 1 (TbKHC1), 
which induces IL­10 and arginase­1, signals through SIGN­R1 in 
myeloid cells and downregulates inducible nitric oxide synthase 
activity (53). In turn, this stimulates the production by the host 
of l­ornithine and hereby the synthesis of polyamines, which 
promotes early parasite growth (54). Consequently, IL­10/argi­
nase­1­producing immune cells are impaired in their capacity to 
destroy the parasite, favoring parasite settlement. Another factor 
trypanosomes use to establish infection is the T. brucei adenylate 
cyclase, which converts ATP into cyclic adenosine monophos­
phate (cAMP) and is upregulated upon phagocytosis by M1 cells 
(55). This phenomenon leads to the inhibition/suppression of 
macrophage activation and consequently to an impaired produc­
tion of parasite controlling molecules (56–59). Hence, it seems 
that trypanosomes have developed a system, where altruistic 
phagocytosed parasites can “temporarily” tempering/disabling 
FiGURe 1 | The activation state of myeloid cells correlates with anemia development during trypanosome infections in trypanosusceptible and trypanotolerant 
animals. (A) Anemia development in trypanosusceptible (green) and trypanotolerant (blue) animals during the course of infection. Anemia progression can be divided 
into (i) an acute phase characterized by a rapid drop in red blood cell (RBC) numbers (i.e., consumptive anemia) followed by a partial recovery phase, (ii) a late stage 
characterized in the susceptible model by a progressive decline in RBC numbers (below that of the acute phase) and host death. In the tolerant model, this decline is 
less pronounced and leads to (iii) a chronic phase (i.e., progressive anemia), whereby RBC numbers keep on declining till finally reaching levels of that of the acute 
phase. (B) Throughout the course of infection progressive hepatosplenomegaly occurs, whereby the onset of splenomegaly precedes hepatomegaly. At the late/
chronic stage of infection, splenomegaly is more pronounced than hepatomegaly. (C) During the different stages of infection, the host produces different mononuclear 
phagocyte system (MPS) polarizing molecules. During the early/acute stage, both trypanosusceptible (upper, green) and trypanotolerant (lower, blue) animals produce 
IFN-γ (green line) required to trigger the induction of classically activated macrophages (M1), which is followed by a moderate induction of IL-10 (blue line) to dampen 
the pathogenic effects of the M1. Only in the trypanotolerant model, there is a second progressive increase in IL-10 during the late/chronic phase of infection, which is 
required to induce alternatively activated macrophages (M2). (D) Occurrence of M1 and M2 during the course of aggressive Trypanosoma brucei or T. brucei 
attenuating strategies (GPI-based strategy or AAV-10/anti-CD28) or less virulent T. brucei PLC−/−/Trypanosoma congolense infection.
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the M1­mediated innate immune response required for parasite 
control (see Figure 2). In turn, this favors the induction of M2 
and paves the way for initiation and establishment of the first 
wave of parasitemia.
Following initial infection, trypanosomes also “deliberately” trig­
ger in a well­timed manner host cellular responses, whereby myeloid 
cells get activated via the combined exposure of (i) parasite­released 
components (i.e., pathogen­associated molecular patterns) such 
as the soluble and membrane­bound/glycosylphosphatidylinositol 
(GPI)­anchored VSG (sVSG and mfVSG, respectively) and CpG­
DNA and (ii) NK/NKT/T­cell released IFN­γ, which most likely is 
mediated via a trypanosome­lymphocyte­triggering­factor (TLTF) 
(see Figure 2, right panel) (45, 60–64). This combination triggers 
the activation of M1 cells, which in turn release pro­inflammatory 
molecules such as tumor necrosis factor (TNF­α) and nitric oxide 
(NO). However, the timing of exposure of these (parasite­ and 
host­derived) components is pivotal in the development of the 
immune response toward the parasites. These key events control­
ling host resistance occur within a short time period following 
initial exposure to the parasite­derived components. Indeed, 
trypanosomes can cleave their GPI­anchored VSG molecules from 
the membrane by the trypanosome GPI­phospholipase­C, which 
results in the release of soluble glycosylinositolphosphate VSG 
(GIP­sVSG) and the retention of the dimyristoylglycerol (DMG) 
moiety in the parasites’ membrane (65–68). Both components 
(DMG and GIP­VSG) exhibit a distinct macrophage­activating 
FiGURe 2 | Proposed model for acute anemia development during trypanosome infections in trypanosusceptible animals (i.e., Trypanosoma brucei). During the 
early stage of infection, saliva components in concert with parasite-derived factors such as KHC [fueling parasite nutrient production (i.e., polyamines)] and AdC 
(dampening the potential of M1), temporarily disable/attenuate the M1-mediated innate immune response, thereby allowing parasite initiation/establishment.  
In addition, parasites release TLTF to trigger IFN-γ production by NK/NKT and CD8+ T cells, which will promote M1 cell activation. At the peak of parasitemia,  
these IFN-γ-primed M1 in concert with parasite-derived factors such as GPI-VSG (GIP/DMG) and CpG fuel M1 to produce pro-inflammatory molecules such  
as TNF, MIF, and Gal-3. In turn, TNF in concert with parasite-released extracellular vesicles (EVs) and/or sialidase trigger/enhance RBC senescence and hence 
erythrophagocytosis by M1 cells, leading to the development of acute anemia (i.e., hemophagocytic/consumptive anemia). Both MIF and Gal-3 promote M1 
polarization and at this stage, there is an amplification of the iron homeostasis [i.e., increased iron storage (ferritin) and export (FPN-1)], which triggers extramedullary 
erythropoiesis. MIF also promotes recruitment/retention of mononuclear phagocytes and neutrophils, which in turn fuel the pathogenic effects of M1. At this stage, 
the host transiently produces IL-10, which is required to dampen the pathogenic effects of the M1 and in concert with the extramedullary erythropoiesis results in a 
partial recovery from acute anemia. Abbreviations: TLTF, T-lymphocyte triggering factor; KHC, kinesin heavy chain; AdC, adenylate cyclase; GPI, 
glycosylphosphatidylinositol; GIP, glycosylinosytolphosphate; RBC, red blood cell; MIF, macrophage migration inhibitory factor; Gal-3, galectin-3; FPN-1, 
ferroportin-1; Hemato, hematopoietic; Non-Hemato, non-hematopoietic; DMG, dimyristoylglycerol; VSG, variant surface glycoprotein.
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potential (60, 62). For example, the GIP­VSG moiety is recognized 
by a type A scavenger receptor (SR­A) expressed mainly on 
mononuclear cells (e.g., macrophages and dendritic cells) leading 
to the concentration­dependent activation of NF­κB and MAPK 
pathways and expression of pro­inflammatory genes such as (TNF­
α, IL­6, IL12p40, and granulocyte­macrophage colony­stimulating 
factor) in a MyD88 dependent manner (61, 63). However, the 
fluctuating levels of parasite (e.g., GIP­sVSG) and host (e.g., IFN­γ) 
factors during infection act to control macrophage activity in 
a complex and subtle way, with the outcome determined by the 
concentration of each mediator, the sequential pattern of its pro­
duction, and the microenvironment of the target macrophage (69). 
For instance, during the early/initial stage of infection, the GIP­
sVSG released before a high level of IFN­γ production prevents a 
prominent strong pro­inflammatory immune response and hence 
favors parasite establishment. Yet, if the IFN­γ levels increase this 
will prime macrophages to respond stronger toward the parasite­
derived GIP­sVSG, which in turn will fuel M1 cells to mount a 
prominent pro­inflammatory immune response.
Host-Derived Factors That Affect Myeloid Cell 
Activation during the Early/Acute Stage of 
Trypanosome Infection
Using gene­deficient mice or neutralizing antibodies it was 
shown that the sequential production of IFN­γ by NK, NKT, 
as well as CD8+ and CD4+ T  cells during the early stage of 
trypanosome infection seems to be crucial to initiate acute 
inflammation­associated anemia (70), also termed consumptive 
anemia (71, 72) (see Figure 2, left panel). In this scenario, IFN­γ 
activates M1 cells, which in turn allows parasite elimination/
removal, but at the same time also promotes the M1­mediated 
enhanced uptake of RBCs resulting in a first rapid drop in RBC 
numbers. Indeed, IFN­γ receptor­deficient mice were found to 
exhibit greatly reduced acute anemia levels (73), coinciding with 
a reduced influx of myeloid­derived cells, e.g., neutrophils and 
M1, within the liver that exhibit an impaired erythrophagocytosis 
capacity (70). Increased levels of host­derived IFN­γ furthermore 
induce splenomegaly (71), which is typically observed during the 
acute stage. Recently, Stijlemans et al. (74) demonstrated using a 
TABLe 1 | Overview of acute and chronic anemia development in different 
Trypanosoma brucei-infected mouse strains.
Mouse model Acute anemia Late/chronic 
anemia
Reference
BALB/c + + (41, 42)
C57BL/6 (WT) +++ +++ (41, 42, 74, 83, 90)
aB-cell−/− +++ +++ (42)
aNu/Nu + + (70)
aIFN-γ−/− or IFN-γR−/− + + (70, 73)
aCD8−/− + ++ (70)
aCD4−/− +++ + to ++ (70)




C57BL/6 + AAV-IL-10 ND + (131)
C57BL/6 + GPI-based 
strategy
+ + (95, 132)
aIL-10−/− +++ ND (131)
aTNF−/− + + (59, 83, 118)
aTNF-R1−/− +++ +++ (41)
aTNF-R2−/− ++ + (41)
aLT-α−/− ++ + to +++ (118)
C57BL/6 + L-NAME + ND (84)
aMIF−/− + + (93)
aGal-3−/− + + (133)
+, Mild anemia (<25% drop in RBCs); ++, moderate anemia (25–35% drop in RBCs); 
+++, severe anemia (>35% drop in RBCs); ND, not determined; RBC, red blood 
cell; AAV-IL-10, alternatively, adenoviral delivery of IL-10; Gal-3, galectin-3; MIF, 
macrophage migration inhibitory factor; WT, wild-type; LT-α, lymphotoxin-alpha.
aGene-deficient mice in C57BL/6 background.
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pHrodo­based assay that during the early stage of T. brucei infec­
tion, CD11b+Ly6G+ neutrophils, CD11b+Ly6Chigh monocytic 
cells, as well as splenic CD11b+F4/80+ myeloid cells exhibit an 
enhanced erythrophagocytosis capacity that might account for 
the occurrence of severe acute­stage non­hemolytic anemia. 
Interestingly, it was shown by others that enhanced erythropha­
gocytosis is associated with the mobilization of Ly6Chigh mono­
cytes in a CCR2­dependent manner from the bone marrow 
into the blood (75), which accumulate mainly within the liver 
and subsequently ingest stressed/senescent erythrocytes. These 
cells differentiate into iron­recycling/ferroportin­1 (FPN­1, sole 
iron exporting molecule)­expressing tissue macrophages and 
subsequently into iron­recycling Kupffer­like cells, which is a 
natural mechanism to preserve homeostasis during fluctuations 
of erythrocyte integrity (76).
Host- and Parasite-Derived Factors That Contribute 
to Acute Anemia
It was shown that RBCs from infected (i.e., day 6 postinfection) 
wild­type (WT) mice exhibited an enhanced osmotic fragility and 
an altered fatty acid membrane composition compared with RBCs 
from non­infected WT mice (70). This change in RBC fragility was 
not due to IFN­γ but might be due to host­derived factors such as 
TNF­α produced by M1 cells (77–80). Indeed, TNF­α could be a 
driving force for the observed changes in RBC fragility given that 
it was shown that it can decrease the RBC half­life and thereby 
fuel RBC senescence/elimination (81). The importance of host­
derived factors such as TNF­α in acute anemia development was 
further substantiated by the observation that T. brucei­infected 
TNF­α­deficient (TNF­α−/−) mice exhibited greatly reduced acute 
anemia levels compared with control WT mice (see Table  1). 
Thereafter, RBC levels in TNF­α−/− mice remained elevated. By 
contrast, in the T. congolense model, TNF­α−/− mice exhibited 
similar acute anemia (and chronic) levels as control WT mice 
(82, 83), suggesting that in this model the underlying mechanisms 
of anemia development are different. Besides TNF­α produced 
by activated myeloid cells, NO was also found to be an important 
factor affecting T. brucei­associated acute anemia development. 
Indeed, treating C57BL/6 mice with l­NAME (a typical inhibitor 
of NO synthase) alleviated acute anemia development (coincid­
ing with reduced peak parasitemia) and was proposed to affect 
proliferation of immature erythrocytes or hematopoietic stem 
cells (73, 84). In line with these observations, mice treated with 
corticosteroids (which downregulates NO synthesis) exhibited an 
alleviated anemia development (85). However, more research is 
required to unravel at which level NO affects T. brucei­associated 
acute anemia development.
Also parasite­derived factors such as sialidases in the case 
of T. congolense or extracellular vesicles (EVs) in the case of 
T. brucei infections could contribute to modifications of RBCs 
and thereby promote elimination (77–80). Indeed, it was pro­
posed at least for the murine T. brucei model that during the 
acute stage, trypanosomes release EVs (filled with intracellular 
parasite cargo as well as VSG) that can fuse with RBCs. This 
causes a change in the physical properties of the RBC membrane, 
which enhances erythrophagocytosis and thereby fuels anemia 
development. In this context, it could be that binding of mfVSG 
(present in the EVs) to the RBC surface sensitizes erythrocytes to 
anti­VSG antibody­mediated complement lysis (86). In addition, 
this observation might also explain how active adenylate cyclase, 
playing a key role in increasing cAMP in host cells resulting in 
the activation of protein kinase A and downregulation of TNF­α, 
could be transferred from the parasite to the mammalian host 
(see above). Indeed, the highly fusogenic EVs containing this 
enzyme might be transferred to recipient host cells, thereby 
increasing the intracellular levels of cAMP. Given that these EVs 
are mainly produced at the peak of parasitemia, they might in 
one way stimulate RBC elimination and at the same time dampen 
sub sequent inflammatory reactions, thereby allowing the next 
wave of parasites to escape. Also for the murine and bovine 
T. congolense model, factors such as congopain and sialidases 
were suggested to contribute directly/indirectly to anemia deve­
lopment, by damaging RBCs that results in the exposure of 
erythrophagocytosis promoting targets (phosphatidylserine) on 
the RBC membrane (78, 87, 88).
Different factors might account for the occurrence of acute 
anemia in both the T. brucei as well as the T. congolense murine 
infection model. Hence, the acute stage of anemia could be due 
to a “natural” reaction of the host following infection as well 
as to parasite­derived factors resulting in a rapid drop in RBC 
numbers due to enhanced erythrophagocytosis (89). At this stage 
of infection, due to the enhance erythrophagocytosis, there is an 
amplification of the iron­homeostasis metabolism (90), resulting 
in an increased release of iron to fuel the enhanced demand for 
erythropoiesis (Figure 2, right panel).
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Transition from Acute to Chronic Anemia: The 
Recovery Phase
Following this acute anemia phase, there is a transient recovery 
phase in both the T. brucei as well as the T. congolense infec­
tion model (see Figure 1), as a natural response of the host to 
control/alleviate acute anemia development. Of note, within the 
T. brucei infection model, this recovery was more pronounced 
in the IFN­γR−/−, CD8−/−, TNF­α−/−, and TNF­R2−/− mice, sug­
gesting that a reduced early pro­inflammatory response/insult 
allows better recovery from acute anemia. However, so far, the 
exact mechanism(s) involved are not well characterized. From 
other experimental models of acute anemia (phenylhydrazine­
induced injection or bleeding), it could be inferred that this is 
most likely due to an enhanced extramedullary erythropoiesis 
occurring mainly in the spleen and to a lesser extent in the liver 
and coincides with the occurrence of hepatosplenomegaly. In this 
context, both in the T. brucei and T. congolense infection model, 
hepatosplenomegaly has been documented starting already dur­
ing the early stages of infection, and coincided with an increase in 
immature RBC numbers within the splenic compartment (91–95). 
It is generally known that anemia induces tissue hypoxia, which 
in turn triggers the activation of a physiological stress response 
(i.e., stress erythropoiesis) designed to increase oxygen delivery to 
tissues by rapidly generating large numbers of erythrocytes (96). 
Moreover, tissue hypoxia triggers the induction of erythropoietin 
(EPO) in the kidney (97), which drives the expansion and dif­
ferentiation of erythroid progenitors. Of note, during murine and 
bovine trypanosome infections, serum EPO levels are increased 
during both the acute and chronic stage of infection (83, 98). 
Subsequently, the bone marrow progenitor cells migrating into 
the spleen or stress erythroid progenitors resident in the spleen 
expand and differentiate in response to bone morphogenetic 
protein 4 (BMP4) and Hedgehog, which act in concert with 
signals previously associated with stress erythropoiesis, such 
as EPO, stem cell factor and hypoxia, to replenish the pool of 
stress erythroid progenitors (96, 99, 100). Whether macrophages 
play also a role at the level of erythropoiesis within the African 
trypanosome model remains to be further investigated. However, 
it was shown that upon anemia or stress, macrophage­dependent 
erythropoiesis (within erythroblastic islands) is needed to 
adequately respond to produce enough erythrocytes to allevi­
ate the shortage (101, 102). Interestingly, in experimental 
T. congolense infections in rats, erythroblastic islands were found 
to expand already during the early stages of infection within the 
bone marrow (103). It is important to mention that following this 
prominent pro­inflammatory immune response and coincid­
ing with the partial recovery of acute anemia, the host is able 
to trigger a “transient” anti­inflammatory immune response, 
whereby IL­10 was shown to play a key role (104, 105). At this 
stage, CD4+ T cells were shown to be important IL­10­producing 
cells to dampen the pathogenic effects of the IFN­γ­induced M1 
(106). Yet, it can not be excluded that other cells (hematopoietic 
or non­hematopoietic) might also contribute (see Figure 2, right 
panel). Recently, it was also suggested that IL­27 can play a key 
role in dampening the pathogenic effects of T  cell­mediated 
IFN­γ during T. brucei and T. congolense infection without affect­
ing IL­10 levels (107).
Myeloid Cells As Key Players during the 
Late/Chronic/Progressive Stage of 
Trypanosomiasis-Associated Anemia 
Development
Following partial recovery from acute anemia, there is a new 
equilibrium established, which is different from the steady­state 
situation (see Figure  1). At this stage, the capacity of the host 
to keep the balance between erythrophagocytosis and eryth­
ropoiesis determines whether anemia persists. This also allows 
discriminating between susceptible and tolerant animals as far as 
anemia is concerned, whereby the activation stage of the myeloid 
cells determines the degree of anemia. Indeed, on one hand, 
trypanosusceptible animals maintain a prominent/polarized M1 
activation state and exhibit progressive anemia (i.e., T. b. brucei 
model), which resembles anemia of chronic disease or anemia 
of inflammation (90). This is characterized by an enhanced 
erythrophagocytosis and impaired/reduced erythropoiesis that 
is linked to a perturbed iron homeostasis including altered iron 
recycling by macrophages and iron sequestration (Figure  2). 
Therefore, the iron­processing pathway is skewed toward iron 
sequestration (40, 90), as evidenced by increased ferritin expres­
sion (main iron storage molecule) and reduced FPN­1 (sole 
iron exporter), while enhanced uptake of RBC/iron­containing 
compounds is maintained (see Figure 3, left panel). Moreover, 
iron sequestration by cells of the MPS can fuel their M1­type 
activation status and limit iron availability for erythropoiesis 
(108–111), thereby contributing to the persistence of anemia.
In this context, it was shown that pro­inflammatory cytokines 
such as IFN­γ, TNF, IL­1, and IL­6 can affect iron­homeostasis 
regulation as well as erythropoiesis. Indeed, during homeostasis, 
there is a balance between RBC destruction and production, 
where the iron availability is adequate to accommodate the 
host’s erythropoietic demand (112). Yet, during inflammation 
this balance is shifted toward an enhanced RBC destruction and 
impaired/insufficient production or RBCs, leading to anemia. 
These pro­inflammatory cytokines trigger (i) the upregulation of 
the divalent metal transporter­1, which increases iron uptake by 
the reticuloendothelial cells, (ii) an enhanced ferritin expression 
(i.e., iron storage molecule), and (iii) a downregulation of FPN­1 
expression thereby promoting iron retention within the MPS (113, 
114). This will cause a deprivation of iron from erythropoiesis. At 
the same time, these pro­inflammatory cytokines inhibit eryth­
ropoiesis by (i) downregulating EPO receptors thereby impairing 
the EPO­mediated effects, (ii) increasing erythroid apoptosis, 
and (iii) antagonizing pro­hematopoietic factors (115, 116).
On the other hand, trypanotolerant animals are able to switch 
to a protective anti­inflammatory response (induced via IL­10), 
which is reflected by the occurrence of M2 cells that in concert with 
IL­10 are able to dampen the pathological effects of the M1 cells, 
and exhibit an alleviated anemia development [i.e., T. brucei atte­
nuation strategies, phospholipase­C­deficient (PLC−/−) T. brucei  
and T. congolense model]. Moreover, trypanotolerant animals 
in contrast to trypanosusceptible animals exhibit a restored 
iron homeostasis (i.e., an enhanced FPN­1 and reduced ferritin 
expression) and increased iron availability for erythropoiesis 
(95). In addition, M2 cells exhibit a reduced erythrophagocytosis 
FiGURe 3 | Proposed model for pathogenicity development during the late/chronic stage of infection in trypanosusceptible and trypanotolerant animals. (Left panel) 
Following recovery from acute anemia (see Figure 2), trypanosusceptible animals are unable to trigger a second wave of IL-10 production resulting in persistence  
of M1, which is most likely promoted via macrophage migration inhibitory factor (MIF) and galectin-3. These M1 produce TNF that further promotes 
erythrophagocytosis and exhibit iron accumulation [increased ferritin and reduced ferroportin-1 (FPN-1) expression], resulting in iron deprivation from erythropoiesis 
and collectively leading to progressive anemia development. MIF also promotes myeloid cell recruitment/retention leading to liver injury. By contrast, in 
trypanotolerant animals, following the acute stage of infection, hematopoietic (hemato) or non-hematopoietic (non-hemato) cells produce IL-10, which dampens the 
pathogenic effects of the M1 by triggering the induction of M2. These M2 exhibit reduced erythrophagocytosis and reduced iron retention, leading to a more efficient 
erythropoiesis and in turn to reduced progressive anemia development. IL-10 also reduces liver injury by dampening the pathogenic effects of the M1. (Right panel) 
However, the chronic production of MIF by M1 and persistent IL-10 production can collectively promote progressive hemodilution, which is most likely due to 
enhanced (hepato)-splenomegaly. In turn, the hemodilution will cause an apparent anemia development in trypanotolerant animals, resulting in thrombocytopenia 
and impaired coagulation in infected mice. The heme catabolism following the chronically induced erythrophagocytosis leads to iron accumulation in myeloid cells 
and to hyperbilirubinemia. The combination of liver injury and hemodilution leads to declined serum albumin levels, thereby preventing efficient removal of toxic 
molecules from the circulation, including bilirubin, and cause multiple organ failure that culminates in reduced survival of the infected host.
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capacity, whereby iron homeostasis is skewed toward export 
(117). It is important to mention that in both the T. brucei and 
T. congolense infection model, the host is able to produce IL­10 
during the acute stage of anemia to dampen the pathogenic 
effects mediated via the pronounced pro­inflammatory response, 
which is linked to the first wave of parasitemia control. However, 
it seems that in the T. brucei (susceptible) model the host is 
unable to retrigger IL­10 induction to dampen the second wave 
of inflammation, while in the PLC−/− T. brucei/T. congolense 
(tolerant) model the host is able to mount a second progressive 
IL­10 response, which is sufficient to dampen the lower level of 
inflammation. This difference in ability to trigger a second wave 
of IL­10 (or alternatively, maintain an IL­10 triggering potential) 
is also reflected at the level of differences in M1 and M2 between 
susceptible and tolerant animals.
Myeloid Cell Activation in the T. brucei (Susceptible) 
versus T. congolense (Tolerant) Model
As far as the T. brucei model (using AnTat1.1E) is concerned, 
there is a persistent M1 activation contributing to severe 
anemia and tissue injury (see Figures 1 and 3). It was shown 
that the TNF­family members [TNF­α and lymphotoxin­alpha 
(LT­α)] play a key role in chronic/progressive anemia develop­
ment by signaling via their dedicated receptors [TNF­R1 or p55 
(CD120a), TNF­R2, or p75 (CD120b)] (see Table 1) (118). Thus, 
TNF­α­deficient (TNF­α−/−) or TNF­R2­deficient (TNF­R2−/−) 
mice exhibited greatly reduced chronic anemia compared with 
WT or TNF­R1­deficient (TNF­R1−/−) mice (41, 59), suggesting 
that TNF­R2 signaling mediates infection­associated pathol­
ogy, whereas TNF­R1 signaling has little or no impact on the 
T. brucei infection. Moreover, the serum levels of soluble TNF­
R2 after shedding, which impaired TNF­α­signaling pathways 
in myeloid cells, correlated with the inhibition of TNF­mediated 
immunopathology. Moreover, the low ratio of total TNF­α to 
soluble TNF­R2 observed in BALB/c mice may account for 
the lack of TNF­mediated pathology, whereas an increased 
ratio in C57BL/6 mice coincided with the severe pathology/
anemia. Using LT­α−/− mice, it was shown that the TIP sequence 
(i.e., lectin­like domain) of TNF­α does not seem to play a role 
in anemia development (118). Importantly, TNF­α and LT­α 
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have high amino acid sequence homology and both bind to the 
TNF­α p55 and p75 receptors (TNF­R1 and ­R2, respectively) 
as soluble homotrimers (119), yet they exhibit alterations in the 
TIP sequences (120). For example, TNF­α exerts a lectin­like 
affinity for several carbohydrate sequences while LT­α does not 
(121). These LT­α−/− mice were shown to exhibit during the 
middle stage of infection (days 10–28) a greatly reduced anemia 
compared with WT mice, which coincided with reduced TNF­α 
induction in LT­α−/− mice during this stage. However, during 
the final stage of infection, serum TNF­α reaches the same 
levels in both LT­α−/− and WT mice, concomitant with similar 
anemia levels in both mice groups. A possible explanation for 
this might be that TNF­α is also an important negative regula­
tor of erythropoiesis and this aspect might predominate at later 
stages of infection (51, 122). Hence, strategies to reduce TNF 
signaling or allowing switching from M1 toward M2 might also 
be valuable to alleviate chronic anemia development. Different 
factors were found to contribute to the ability of the host to 
switch from M1 to M2 and the ability to maintain/trigger IL­10 
during the later stages was shown to be detrimental to attenuate 
anemia.
Collectively, it seems that the mechanisms underlying 
trypa nosomiasis­associated anemia are multifactorial and the 
relative contribution of each mechanism will differ according 
to the host–parasite model, the phase of anemia development 
and the severity of infection and is probably caused by massive 
extravascular erythrophagocytosis by an expanded MPS in con­
cert with an inadequate erythropoiesis.
POTeNTiAL iNTeRveNTiON STRATeGieS 
TO ALLeviATe AT-ASSOCiATeD ANeMiA
The Parasite Strain Used Determines  
the MPS Activation State and Anemia 
Development
Typically, in the experimental T. brucei C57BL/6 model, the 
myeloid cells are polarized into an M1 state, which is pro­
moted due to the inability of the host to sustain a strong anti­ 
inflammatory immune response. By contrast, in the less aggres­
sive model experimental PLC−/− T. brucei C57BL/6 model, there 
is a switch from M1 toward M2 mediated via IL­10, coinciding 
with reduced pathology (anemia/tissue injury) and prolonged 
survival. A possible explanation for this switch toward M2 in 
the PLC−/− T. brucei model and not in the WT T. brucei model 
might rely in the fact that the PLC is required to sustain M1 
by (i) allowing the release of GPI­anchored proteins (encom­
passing the GIP) to stimulate macrophages to secrete pro­
inflammatory molecules (TNF­α, IL­1, IL­6, and NO) and/or 
(ii) trigger CD1d­restricted NKT cells to secrete IFN­γ thereby 
triggering a very strong type 1 immune response (60, 123). 
Indeed, it was shown that in the PLC−/− T. brucei C57BL/6 
model the lower parasitemia coincided with reduced early 
IFN­γ production and subsequent attenuated MPS­derived 
pro­inflammatory cytokine production, reflecting a reduced 
type 1 immune response mounted (124–126). The crucial role 
of IFN­γ and IL­10 during infection was further substantiated 
using gene­deficient mice, where the absence of IL­10 coin­
cided with high pathology and early mortality. Although the 
source of IL­10 was not thoroughly investigated within the 
PLC−/− T. brucei model, some data suggest the involvement of 
CD4+ T cells (124). Interestingly, infections of PLC−/− T. brucei 
parasites using C57BL/6 x BALB/c (B6B­F1) mice were found 
to exhibit striking similarities with that of the trypanotolerant 
N’Dama cattle naturally infected with T. congolense. These 
latter include (i) lower parasitemia, (ii) prolonged survival, 
(iii) increased type II and decreased type I immune responses, 
and (iv) reduced pathology and minimal clinical symptoms 
during the course of infection (127, 128). Therefore, PLC−/−  
T. brucei­infected B6B­F1 mice represent a suitable model to 
study the immune responses during bovine T. congolense infec­
tions. Within the T. congolense model in C57BL/6 mice, it was 
shown that spleen and liver regulatory T cells (Foxp3+ Tregs) 
were an important source of IL­10, thereby limiting the produc­
tion of early IFN­γ by T cells and in that way lowering patho­
logy. Besides Tregs, also myeloid­derived IL­10 was shown to 
play an important role in limiting the production of pathogenic 
TNF­α by M1 cells (characterized as CD11b+Ly6C+) through 
induction of nuclear translocation of the NF­κB p50 member 
(129). However, it cannot be excluded that other hematopoietic 
and non­hematopoietic cells can be potential sources of IL­10 
during the course of T. congolense infection (Figure 3).
iL-10-inducing Strategies to Modulate  
the MPS Activation State and Anemia 
Development
As mentioned before, the capacity of the host to induce IL­10 
immediately after the induction of a prominent pro­inflammatory 
immune response mediated via M1 cells determines whether 
pathology/anemia develops/is alleviated or not. This opens per­
spectives for potential IL­10 triggering/promoting intervention 
strategies aiming at triggering an M1 toward M2 switch, thereby 
reducing pathology development. So far, several strategies have 
been used to demonstrate/strengthen the pivotal role of IL­10 
in reducing trypanosomiasis­associated pathogenicity using the 
susceptible T. brucei model. For instance, transient anti­CD28 
superagonist antibody treatment (inducing regulatory T cells and 
M2) in the T. brucei model attenuated acute anemia development 
(130). Given that this treatment was not continued during the 
chronic phase of infection its effects during this stage remain 
to be determined. Alternatively, adenoviral delivery of IL­10 
in the T. brucei model coincided with an alleviated pathology/
anemia development (131), during the chronic phase of infection 
(see Table  1). Also a GPI­based treatment strategy, where the 
parasite­derived GPI moiety (i.e., most potent parasite­derived 
TNF­inducing molecule involved in M1 triggering) was used 
to reprogram macrophages toward an anti­inflammatory state 
(i.e., reflected by a reduced inflammatory cytokine production 
and increased IL­10 production), was shown to alleviate anemia 
in both clonal as well as natural/non­clonal T. brucei infections 
(132). This strategy allowed reducing RBC destruction, normal­
izing iron homeostasis (i.e., a shift in increased liver expres­
sion of iron storage toward iron export genes) and restoring 
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erythropoiesis [i.e., increased erythropoiesis in the bone marrow 
and extramedullary sites (spleen)] (95). Interestingly, this GPI­
based treatment also alleviated “chronic” anemia development 
during experimental T. congolense as well as T. evansi infections 
suggesting a wide applicability.
M1-Promoting Factors Are Prime Targets 
to Attenuate Anemia
Given that M1 cells are major contributors to anemia develop­
ment, identification of M1­derived pathological factors might 
open perspectives to attenuate the pathology. An approach to 
identify potential M1­derived pathology inducing/promot­
ing factors consisted of scrutinizing a GPI­based strategy, 
which enabled a straightforward comparison between tryp­
anotolerance and trypanosusceptibility in T. brucei­infected 
C57BL/6 mice, independent of the genetic background of the 
host (95). A resulting comparative gene expression analysis 
of M1­polarizing molecules and/or molecules involved in 
enhancing erythrophagocytosis identified galectin­3 (Gal­3) 
and macrophage migration inhibitory factor (MIF) as potential 
candidates. Both molecules were indeed found to contribute to 
anemia development during T. brucei infections by affecting/
regulating different aspects of the host’s immune response. As 
far as Gal­3 (i.e., a family member of beta­galactoside­binding 
animal lectins) is concerned, it was shown that Gal-3−/− mice 
manifested higher IL­10 levels that can exert an influence on 
iron uptake and counteract the effects of IFN­γ (133). Hence, 
Gal­3 can promote persistence of M1 and regulate the expres­
sion of iron­homeostasis genes, favoring iron storage, which 
ultimately culminates in iron shortage for erythropoiesis and 
exacerbate inflammation­associated anemia development 
(Figures 2 and 3) (133, 134). In addition, given the negative 
effect of Gal­3 on the induction of IL­10, a persistent inflam­
matory response is ensured in presence of Gal­3. As far as MIF 
is concerned, this “early response” cytokine is expressed by 
numerous cell types, including myeloid cells, plays a key role 
in innate and adaptive immunity and was shown to be involved 
in many protozoan infections (135–137). Using Mif−/− mice it 
was shown that this upstream regulator of the inflammatory 
cascade contributed to inflammation­associated pathogenicity 
by (i) sustaining a persistent pro­inflammatory type I immune 
response (impairing IL­10 production) and (ii) maintaining/
enhancing the recruitment of pathogenic monocytic cells and 
neutrophils in the liver whereby neutrophil­derived MIF con­
tributed significantly to enhanced TNF production and liver 
damage (Figures 2 and 3) (93). The pivotal role of MIF within 
the African trypanosomiasis model regarding the persistence 
of inflammation might be multifactorial. For instance, endoge­
nous MIF has been shown to (i) promote macrophage­mediated 
inflammatory responses via induction of CC chemokine ligand 
2 expression, thereby promoting the recruitment of monocytes 
into affected areas and (ii) exert a regulatory role in cellular 
responsiveness to key pro­inflammatory cytokines TNF and 
IL­1 via upregulation of cytokine receptor­dependent MAPK 
signaling (i.e., upregulation of TNF­R1 and IL­1R expression, 
respectively) independent of NF­κB (138, 139). Hence, by 
both attracting and activating monocyte/macrophages, MIF 
may contribute to the initiation and perpetuation of detri­
mental inflammation associated with diseases such as African 
trypanosomiasis. In addition, MIF importantly contributed 
to anemia development by (i) promoting iron accumulation 
in liver myeloid cells, (ii) enhancing RBC clearance, and 
(iii) suppressing erythropoiesis at later stages of erythroblast 
differentiation (Figure  3) (93). Interestingly, MIF was also 
shown to be a potential pathogenic molecule playing a key role 
in chronic anemia development during T. congolense infections 
by (i) promoting erythrophagocytosis, (ii) blocking extramed­
ullary erythropoiesis and RBC maturation, and (iii) triggering 
hemodilution (Figure 3) (94).
Overall, it seems that during murine T. brucei and T. congolense 
infections anemia is mainly due to enhanced erythrophagocy­
tosis combined with enhanced but inadequate extramedullary 
erythropoiesis. Yet, during T. congolense but not T. brucei infec­
tions, hemodilution (involving massive hepatosplenomegaly) 
seems to be an additional factor contributing to chronic anemia 
development (93, 94). However, it might be that within the 
T. brucei model the contribution of hepatosplenomegaly to 
hemodilution is minor or not reached within this “short” time 
period. This notion is strengthened by the fact that there was 
no correlation between anemia and hemodilution (involving 
hepatosplenomegaly) in T. brucei and T. congolense­infected 
rats within the same time window (92). However, a different 
T. brucei parasite strain (TREU 667 strain) causing a more 
chronic infection involving also revealed that the hepatosple­
nomegaly could contribute to hemodilution (140). Of note, also 
in HAT patients exhibiting anemia during later stages of the 
disease, hepatosplenomegaly has been recorded and this might 
therefore contribute to the observed “apparent” anemia (28). In 
this particular model, it seems that the virulence of the parasites 
determines whether hemodilution occurs. Interestingly, these 
observations correlate nicely with experimental T. brucei and 
T. congolense infections in domestic animals (cattle and sheep, 
respectively) (141, 142). Importantly, it was shown that MIF 
can also be present in erythrocytes and upon (hemo)lysis, due 
to oxidative stress, this factor can be released to further fuel 
inflammation (143). Given that hemolysis was shown to occur 
during T. congolense infections (40, 144), the increased levels of 
MIF observed during both the acute and chronic stage might 
mainly be due to parasite­inflicted rather that host­mediated 
damage of RBCs, which could also fuel a chronic (low­grade) 
anemia profile. Therefore, MIF might be an “important” player 
(upstream regulator) in African trypanosomiasis­associated 
anemia, mainly during the chronic stage of anemia development 
by fueling/promoting pathogenic M1 and could be considered 
as a prime anti­disease target.
GeNeRAL CONCLUSiON AND 
PeRSPeCTiveS
African trypanosomes are very proficient in sculpturing a 
temporal environment to allow a gradual parasite establish­
ment (27). Hereby, the host’s response at different stages of the 
11
Stijlemans et al. MPS and Trypanosomiasis-Associated Anemia
Frontiers in Immunology | www.frontiersin.org February 2018 | Volume 9 | Article 218
infection determines whether pathogenicity/anemia develops. 
The mechanisms underlying African trypanosomiasis­associated 
anemia are multifactorial, whereby various molecules influ­
ence differentially the progression/development of anemia at 
distinct stages of infection. Initially, acute anemia seems to 
develop as part of the innate immune response upon infec­
tion, where parasite­derived factors, such as parasite­derived 
EVs, as well as host­derived (parasite­induced) IFN­γ trigger 
M1 cell differentiation that in turn produce pro­inflammatory 
molecules to control the infection. In this context, IFN­γ 
produced at the acute stage is the driving factor leading to 
acute/hemophagocytic anemia (30). In addition, the release 
of parasite­derived EVs in concert with host­derived TNF­α 
affect RBC survival and thereby fuels RBC elimination trough 
erythrophagocytosis (Figure  2). This is followed by a partial 
recovery, mediated most likely via extramedullary erythropoie­
sis, as a homeostatic reaction and a transient IL­10 production 
to dampen the pathogenic effects of the M1. Depending on the 
level of insult (i.e., M1­induced damage) and the capacity of the 
host to trigger and subsequently maintain IL­10 production, 
anemia is either alleviated (i.e., trypanotolerant animals) or 
sustained (i.e., trypanosusceptible animals). At this stage, MIF 
is an important host­derived factor determining/regulating 
the progression of anemia by promoting a persistent pro­ 
inflammatory immune response and suppressing erythro­
poiesis. In addition, IFN­γ, TNF­α, and MIF are important 
molecules exerting a negative effect on erythropoiesis and at 
the same time at promoting erythrophagocytosis. By contrast, 
IL­10 was shown to positively affect erythropoiesis by down­
regulating the effects of the pro­inflammatory cytokines (145). 
Therefore, the balance between these pro­ and anti­inflam­
matory cytokines during the course of infection determines 
the course of anemia development (51). In other words, the 
ability of the host to mount an efficient erythropoietic response 
(stress­induced response) to compensate for the enhanced 
erythrophagocytosis determines whether anemia persists. In 
the murine model, but also in cattle, the erythropoietic poten­
tial determines the level of anemia (33, 40, 94, 122). However, 
it seems that chronic anemia is most likely host­inflicted and 
due to a disproportional immune response (30). In summary, 
the mechanisms underlying/promoting chronic anemia deve­
lopment during T. brucei and T. congolense infections seem to 
be different. In the T. brucei infection model the main driving 
forces for anemia development are (i) the persistence of M1 
that promote enhanced RBC elimination and iron retention 
and (ii) an insufficient erythropoiesis due to iron deprivation 
and the presence of pro­inflammatory cytokines that suppress 
RBC differentiation/maturation (Figure  3). By contrast, in 
the T. congolense infection model these aspects seem to play a 
main role only during the acute stage, as once M2 are induced 
and expanding they can in concert with IL­10 dampen to a 
certain extent the pathogenic effects of the M1. Given that 
T. congolense­infected animals still exhibited chronic anemia 
despite the presence of M2 and IL­10 suggests that the under­
lying mechanisms of chronic anemia in this model might be 
different and might rely on the hematopoietic potential of the 
animals (40). It was proposed that the month­lasting low­grade 
inflammatory response can also drive erythrophagocytosis, 
where the ensuing catabolism of hemoglobin resulted in iron 
accumulation mainly in the spleen and is followed by the 
enhanced release of bilirubin in the blood circulation (94). The 
resulting hyperbilirubinemia could favor the externalization 
of phosphatidylserine on RBCs and thus further contribute 
to erythrophagocytosis or eryptosis during T. congolense 
infection (146). However, at this stage the persistence of IL­10 
might be a double­edged sword by on one hand dampening 
tissue injury and reduce the suppression on erythropoiesis 
mediated by the M1­released pro­inflammatory mediators 
and on the other promoting (i) ferritin expression thereby 
indirectly affecting iron availability, (ii) thrombocytopenia, 
and (iii) splenomegaly, leading to hemodilution (147, 148). The 
latter might in turn culminate into the occurrence of appar­
ent anemia development, despite an enhanced erythropoiesis 
activity. In this context, it was shown that sustained secretion 
of IL­10 from transduced muscle leads to thrombocytopenia 
and splenomegaly in mice injected with rAAV1­IL­10 (147). 
Interestingly, thrombocytopenia was also documented for 
T. congolense­infected animals (149, 150). The splenomegaly 
observed in both susceptible and tolerant animals is required 
to accommodate the increased demand for erythropoiesis 
(93–95). However, it seems that this excessive accumulation of 
immature RBCs is most likely due to an inefficient erythropoi­
etic potential (e.g., iron retention or unresponsiveness toward 
EPO or inefficient functioning of erythroblastic islands). 
Indeed, it was shown that most genes involved in erythropoiesis 
were found to be significantly modulated during the course of 
both T. brucei and T. congolense infection (40, 93, 94). However, 
so far information regarding erythropoiesis during African 
trypanosomiasis is limited and requires more attention. Also, 
a possible involvement of macrophages (functionality) within 
erythroblastic islands requires consideration. Within the era 
of genomics/proteomics (151–154), we can assume that novel 
pathways, mechanisms and molecular target molecules will be 
identified in various mouse models (155, 156). These discover­
ies will help us to refine our understanding of the mechanisms 
underlying anemia development and could even pave the way 
to develop new intervention strategies to alleviate it.
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